DEC 06, 2021 3:00 AM PST

Young Patients with Lymphoma Benefit from Chemotherapy Combination Treatment

WRITTEN BY: Katie Kokolus

The most common form of non-Hodgkin lymphoma is diffuse large B-cell lymphoma (DLBCL). DLBCL is a fast-growing cancer that grows in B cells, the immune cells that make antibodies to fight infection. Over 18,000 people are diagnosed with DLBCL in the United States each year.  

One subgroup of DLBCL is characterized by a genetic pattern described as “activated B cell-like” (ABC).  Tumors of the ABC subtype require chronic B cell receptor signaling, a function inhibited with a targeted therapy called ibrutinib.    

A new study published in Cancer Cell suggests that a targeted therapy called ibrutinib administered in combination with a standard chemotherapy regimen significantly benefits some DLBCL patients. Although DLBCL is most common in adults over 60 years, the study focused on patients under 60.  This cohort that demonstrated a survival benefit in a previous Phase III trial, the Phoenix Trial, investigating a similar combination therapy.  

All patients received standard R-CHOP chemotherapy consisting of rituximab, cyclophosphamide, hydroxydaunomycin (also known as doxorubicin), oncovin (also known as vincristine), and prednisone.  Patients received R-CHOP with or without ibrutinib. 

The researchers analyzed biopsies from patients on the Phoenix Trial and identified three genetic signatures, MCD, BN2, and N1, within the ABC tumor samples.  When evaluating the MCD and N1 subtypes, the analysis revealed 100% three-year event-free survival in patients under 60 treated with R-CHOP plus ibrutinib.  Patients exhibiting these tumor subtypes treated with R-CHOP alone had less than 50% three-year event-free survival. 

The exciting data presented in the study strongly promotes new personalized medicine strategies for specific patients with DLBCL.  While doctors typically run tests to classify the ABC subgroup, there is no commercial test available to further identify the MCD and N1 subtypes.  More personalized strategies may become feasible as we develop a greater understanding of the underlying mechanisms of combination R-CHOP plus ibrutinib therapy.  Subtyping tumors could help doctors and patients develop more effective personalized treatment strategies.  

 

Sources: DLBCL, B cells, ABC, ibrutinib, Cancer Cell, Phase III trial, R-CHOP

About the Author
Doctorate (PhD)
PhD in Tumor Immunology. I am interested in developing novel strategies to improve the efficacy of immunotherapies used to extend cancer survivorship.
You May Also Like
SEP 25, 2022
Genetics & Genomics
The next generation of library preparation solutions for DNA sequencing
The next generation of library preparation solutions for DNA sequencing
The next generation of library preparation solutions for DNA sequencing  Since the completion of the Human Genome P ...
NOV 23, 2022
Cannabis Sciences
Why researchers have hope that cannabis may help fight ovarian cancer
Why researchers have hope that cannabis may help fight ovarian cancer
There's a positive, growing link between cannabis and the fight against ovarian cancer. Here's why researchers are optim ...
DEC 12, 2022
Cancer
Most Adults Don't Know Alcohol Increases Cancer Risk
Most Adults Don't Know Alcohol Increases Cancer Risk
Many of us indulge in alcohol in some form or another.  The frequency and type of alcohol consumed range from an oc ...
DEC 18, 2022
Drug Discovery & Development
Activated Vitamin D3 May Protect Against Arsenic in Drinking Water
Activated Vitamin D3 May Protect Against Arsenic in Drinking Water
Activated vitamin D3 may protect against various conditions- including skin cancer- that arise after drinking arsenic-co ...
DEC 29, 2022
Genetics & Genomics
Insights Into a Phenomenon of Aging - Clonal Hematopoiesis
Insights Into a Phenomenon of Aging - Clonal Hematopoiesis
Our body generates a lot of blood cells - on the order of billions of cells every day. Stem cells in the bone marrow giv ...
DEC 30, 2022
Health & Medicine
New bacterial therapy approach to treat lung cancer
New bacterial therapy approach to treat lung cancer
Lung cancer is the leading cause of cancer-related mortality in the USA - the five-year relative survival rate is as low ...
Loading Comments...